

Ian M Robertson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2184488/publications.pdf>

Version: 2024-02-01

27
papers

825
citations

687220

13
h-index

580701

25
g-index

27
all docs

27
docs citations

27
times ranked

1320
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 1155-1177.	1.8	252
2	Resveratrol improves exercise performance and skeletal muscle oxidative capacity in heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 312, H842-H853.	1.5	70
3	A structural and functional perspective into the mechanism of Ca ²⁺ -sensitizers that target the cardiac troponin complex. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 1031-1041.	0.9	60
4	Solution Structure of Human Cardiac Troponin C in Complex with the Green Tea Polyphenol, (âˆ™)-Epigallocatechin 3-Gallate. <i>Journal of Biological Chemistry</i> , 2009, 284, 23012-23023.	1.6	59
5	Structural and Functional Consequences of the Cardiac Troponin C L48Q Ca ²⁺ -Sensitizing Mutation. <i>Biochemistry</i> , 2012, 51, 4473-4487.	1.2	41
6	Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes. <i>Cardiovascular Research</i> , 2018, 114, 1350-1359.	1.8	41
7	Interaction of cardiac troponin with cardiotonic drugs: A structural perspective. <i>Biochemical and Biophysical Research Communications</i> , 2008, 369, 88-99.	1.0	39
8	Solution structure of the regulatory domain of human cardiac troponin C in complex with the switch region of cardiac troponin I and W7: The basis of W7 as an inhibitor of cardiac muscle contraction. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 925-933.	0.9	36
9	Structure of <i>trans</i> -Resveratrol in Complex with the Cardiac Regulatory Protein Troponin C. <i>Biochemistry</i> , 2011, 50, 1309-1320.	1.2	33
10	Defining the Binding Site of Levosimendan and Its Analogues in a Regulatory Cardiac Troponin Câˆ™Troponin I Complex. <i>Biochemistry</i> , 2008, 47, 7485-7495.	1.2	32
11	The Dilated Cardiomyopathy G159D Mutation in Cardiac Troponin C Weakens the Anchoring Interaction with Troponin I. <i>Biochemistry</i> , 2008, 47, 10950-10960.	1.2	25
12	The structural and functional effects of the familial hypertrophic cardiomyopathy-linked cardiac troponin C mutation, L29Q. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 87, 257-269.	0.9	18
13	Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 92, 174-184.	0.9	16
14	Reversible Covalent Binding to Cardiac Troponin C by the Ca ²⁺ -Sensitizer Levosimendan. <i>Biochemistry</i> , 2016, 55, 6032-6045.	1.2	14
15	Elucidation of Isoform-dependent pH Sensitivity of Troponin I by NMR Spectroscopy. <i>Journal of Biological Chemistry</i> , 2012, 287, 4996-5007.	1.6	13
16	Interaction between the regulatory domain of cardiac troponin C and the acidosis-resistant cardiac troponin I A162H. <i>Cardiovascular Research</i> , 2013, 97, 481-489.	1.8	13
17	Visualizing the principal component of 1H,15N-HSQC NMR spectral changes that reflect protein structural or functional properties: application to troponin C. <i>Journal of Biomolecular NMR</i> , 2011, 51, 115-122.	1.6	12
18	A novel complex I inhibitor protects against hypertension-induced left ventricular hypertrophy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 312, H561-H570.	1.5	12

#	ARTICLE	IF	CITATIONS
19	Reversible Covalent Reaction of Levosimendan with Cardiac Troponin C <i>in Vitro</i> and <i>in Situ</i> . <i>Biochemistry</i> , 2018, 57, 2256-2265.	1.2	8
20	The Evaluation of Isotope Editing and Filtering for Protein-Ligand Interaction Elucidation by Nmr. NATO Science for Peace and Security Series B: Physics and Biophysics, 2009, , 101-119.	0.2	8
21	Conformation of the critical pH sensitive region of troponin depends upon a single residue in troponin I. <i>Archives of Biochemistry and Biophysics</i> , 2014, 552-553, 40-49.	1.4	7
22	Optimizing fluorine labelling for ¹⁹ F solid-state NMR in oriented biological systems. <i>Journal of Biomolecular NMR</i> , 2020, 74, 1-7.	1.6	5
23	The Role of Electrostatics in the Mechanism of Cardiac Thin Filament Based Sensitizers. <i>ACS Chemical Biology</i> , 2020, 15, 2289-2298.	1.6	5
24	Thioimidate Bond Formation between Cardiac Troponin C and Nitrile-containing Compounds. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1007-1012.	1.3	4
25	Structure and Dynamics of the Acidosis-Resistant A162H Mutant of the Switch Region of Troponin I Bound to the Regulatory Domain of Troponin C. <i>Biochemistry</i> , 2015, 54, 3583-3593.	1.2	2
26	Orientation of the Calcium Sensitizing Agent dfbp-o, when Bound to Troponin in a Muscle Fiber as Determined by Solid-State NMR Spectroscopy. <i>Biophysical Journal</i> , 2011, 100, 585a.	0.2	0
27	Approaches to Protein-Ligand Structure Determination by NMR Spectroscopy: Applications in Drug Binding to the Cardiac Regulatory Protein Troponin C. NATO Science for Peace and Security Series B: Physics and Biophysics, 2012, , 121-134.	0.2	0